Evidence map›Paper›PMID 39458961›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Arylpiperazine Derivatives and Cancer: A New Challenge in Medicinal Chemistry.

Giorgia Andreozzi, Angela Corvino, Beatrice Severino, Elisa Magli, Elisa Perissutti, Francesco Frecentese, Vincenzo Santagada, Giuseppe Caliendo, Ferdinando Fiorino

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giorgia AndreozziDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Angela CorvinoDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0002-0617-156X
Beatrice SeverinoDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0002-3887-8869
Elisa MagliDipartimento di Sanità Pubblica, Università di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy.
Elisa PerissuttiDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0002-1754-1191
Francesco FrecenteseDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0001-8821-2937
Vincenzo SantagadaDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Giuseppe CaliendoDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.
Ferdinando FiorinoDipartimento di Farmacia, Università di Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0001-7357-5751

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-proliferative agentsarylpiperazinecancersmall molecules

Identifiers

PMID39458961
PMCPMC11510360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.